• Researcher Profile

    Amanda Redig, MD, PhD

    Amanda Redig, MD, PhD
    Associate Physician

    Instructor in Medicine, Harvard Medical School


    Thoracic Oncology

    Office phone: 617-632-6036
    Fax: 617-582-7683

    Preferred contact method: office phone

    View Physician Profile

    Research Department

    Medical Oncology/Solid Tumor Oncology


    Mechanisms of drug resistance, KRAS, EGFR, Brain Metasteses, Tumor genomics, Targeted therapies, Translational research, Lung cancer

    Area of Research

    Genomics of Non-small Cell Lung Cancer (NSCLC)

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215


    Dr. Redig received her MD and PhD from Northwestern University followed by a residency in internal medicine at the Brigham and Women’s Hospital and a medical oncology fellowship at the Dana-Farber Cancer Institute. Following this postgraduate training at DFCI, she joined the faculty of the Thoracic Oncology Program as a physician-scientist and translational investigator. Her primary research interests include a focus on tumor genomics, precision medicine, and brain metastases.

    Recent Awards

    • A Breath of Hope Lung Foundation Research Fellowship, 2016
    • Conquer Cancer Foundation ASCO Young Investigator Award, 2016


    Genomics of Non-small Cell Lung Cancer (NSCLC)

    As a translational investigator, my major area of research interest is the genomics of non-small cell lung cancer (NSCLC) and how we can better utilize comprehensive tumor sequencing efforts to develop improved therapies for patients and also prevent the development of drug resistance. My ongoing research projects involve analysis of genomic data from cohorts of NSCLC defined by the presence of selected oncogenic driver mutations as well as development of clinical trials. I am also involved in cross disciplinary efforts studying the development and treatment of CNS metastases.

    Select Publications

    • Redig AJ, Jänne PA. (2015) Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol, 33(9):975-7.
    • Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA. (2016). Clinical and molecular characteristics of NF1-mutant lung cancer. Clin Cancer Res, Jul 1;22(13):3148-56.
    • Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 17(7):1051.
    • Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. (2016) Prospective study of repeated biopsy feasibility and acquired resistance at disease progression in patients with advanced EGFR mutant lung cancer treated with erlotinib in a phase II trial. JAMA Oncol Sep 1;2(9):1240-2.
    • Yanagita M,* Redig AJ, *  Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. (2016) A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin Cancer Res, Dec 15;22(24):6010-6020.
    • Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. (2016) Targeting bet bromodomain proteins in solid tumors. Oncotarget, 7(33): 53997-54009.
    • Redig AJ, Jänne PA. (2016) No target left behind: improving therapeutic options for ERBB2-mutant non-small cell lung cancer. J Thoracic Oncol 11(6):784-6.
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer

Give Now